Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 5, 2017, Pages

  Farquhar, Cindy ^a   Rombauts, Luk ^b   Kremer, Jan A M ^c   Lethaby, Anne ^a   Ayeleke, Reuben Olugbenga ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b MONASH UNIVERSITY   (Australia)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; GONADOTROPIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; GONADORELIN;

FEMALE SUBFERTILITY; HUMAN; INFERTILITY THERAPY; LIVE BIRTH; MULTIPLE PREGNANCY; OOCYTE; ORAL CONTRACEPTION; OUTCOME ASSESSMENT; OVARY CYST; OVARY HYPERSTIMULATION; PREGNANCY OUTCOME; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; FEMALE; FEMALE INFERTILITY; IN VITRO FERTILIZATION; INTRACYTOPLASMIC SPERM INJECTION; META ANALYSIS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

CONTRACEPTIVES, ORAL; ESTROGENS; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; LIVE BIRTH; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; PREGNANCY, MULTIPLE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPERM INJECTIONS, INTRACYTOPLASMIC; TREATMENT OUTCOME;

EID: 85019652478     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006109.pub3     Document Type: Review

References (165)

1. Aston K, Arthur I, Masson GM, Jenkins JM. Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology 1995;102:835-7. 2755310
2. Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F. Prospective randomized trial on effect of pre-treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH-a) and subsequent implantation and pregnancy rates. Fertility and Sterility 1998; Vol. Suppl 1, 70, issue 3:S133. 2755313
3. Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility 1998;70(6):1063-9. 2755312
4. Blockeel C, Engels S, de Vos M, Haentjens P, Polyzos NP, Stoop D, et al. Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial. Reproductive Biomedicine Online 2012;24:272-80. 2755315
5. Cédrin-Durnerin I, Bständig B, Parneix I, Bied-Damon V, Avril C, Decanter C, et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Human Reproduction 2007;22(1):109-16. [DOI: 10.1093/humrep/de1340]2755320
6. Hugues JN, Cédrin-Durnerin I, Bständig B, Parneix I, Bied-Damon V, Avril C, et al. Consequences of different steroid pre-treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol. 21st Annual Meeting of the ESHRE; 2005 Jun 19-22; Copenhagen, Denmark. 2005. 2755321
7. Cédrin-Durnerin I, Guivarc'h-Leveque A, Hugues J-N. Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial. Fertility and Sterility 2012;97(6):1359-64. 2755323
8. Daly DC, Daly CL, Mayo D, Jacobs A. Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos. Fertility and Sterility 2002; Vol. Suppl 1, 78, issue 3:S148-9. 2755325
9. DitkoffEC, Sauer MV. A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin-releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Human Reproduction 1996;11(5):1035-7. 2755327
10. Engmann L, Maconochie N, Bekir J, Tan SL. A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999. Fertility and Sterility 1999;72(3, Suppl 1):S10-1. 2755329
11. Engmann L, Maconochie N, Bekir J, Tan SL. Progestogen therapy during pituitary desensitization with gonadotropin-releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. American Journal of Obstetrics and Gynecology 1999;181(3):576-82. 2755330
12. Engmann L, Maconochie N, Tan SL, Bekir J. Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation - a prospective randomized study. Human Fertility. 1999; Vol. 2:190-1. 2755331
13. Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol administration coordinates FSH-induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29-Jul 2; Madrid, Spain, 2003. 2003. 2755335
14. Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction 2003;18(12):2698-703. [DOI: 10.1093/humrep/deg516]2755336
15. a fase com análogos do GnRH (I - estradiol + Ganirelix versus II - Nafarelin)]. Jornal Brasileiro de Reproducao Assistida 2003;7(1):26-32. 2755338
16. Garcia-Velasco JA, Bermejo A, Ruiz F, Martinez-Salazar J, Requena A, Pellicer A. Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility 2011;96(3):590-3. 2755341
17. Garcia-Velasco JA, Bermejo A, Ruiz-Flores F, Martinez-Salazar J, Requena A, Pellicer A. Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial. Fertility and Sterility 2010;94 Suppl 1(4):S28 Abstract no. O-93. 2755340
18. Hauzman EE, Zapata A, Bermejo A, Iglesias C, Pellicer A, Garcia-Velasco J. Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial. Reproductive Biology and Endocrinology 2013;11:96. 2755343
19. Hugues JN, Cédrin-Durnerin I, Hervé F, Huet-Pecqueux L, Santarelli J. Incidence of preprogrammed norethisterone on the intensity of 'flare up' (flush) caused by GnRH agonist according to the IVF protocol [poster] [Incidence d'une préprogrammation par la noréthistérone sur la qualité du flare-up induit par un agoniste du GnRH en protocole court de FIV]. Contraception, Fertilite, Sexualite 1994; Vol. 22, issue 5:331. 2755345
20. Huirne JAF, van Loenen ACD, Donnez J, Pirard C, Homburg R, Schats R, et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online 2006;13(2):235-45. 2755349
21. Van Loenen ACD, Huirne JAF, Schats R, Donnez J, Lambalk CB. An open-label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH-antagonist in patients undergoing ART (IVF-ICSI) treatment. Human Reproduction. 2002; Vol. 17 Abstract Book 1:144-5. 2755350
22. Huirne JA, Hugues JN, Pirard C, Fischl F, Sage JC, Pouly JL, et al. Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction 2006;21(6):1408-15. [DOI: 10.1093/humrep/de1030]2755347
23. Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction 2004;19(9):1993-2000. [DOI: 10.1093/humrep/deh375]2755352
24. Kim C-H, Jeon G-H, Cheon Y-P, Jeon I, Kim S-H, Chae H-D, et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low-dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility 2009;92(5):1758-60. 2755355
25. Kim C-H, You R-M, Kang H-J, Ahn J-W, Lee J-I, Kim S-H, et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre-treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine 2011;38(4):228-33. 2755354
26. Kim CH, Lee HA, Lee JW, Lee YJ, Nah HY, Hong SH, et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Human Reproduction. 2005; Vol. 20 Suppl 1:i105-6. 2755356
27. Kolibianakis EM, Albano C, Tournaye H, Camus M, Van Steirteghem A, Devroey P. Pre-treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec-FSH and GnRH antagonists. Fertility and Sterility 2003; Vol. 80, issue Suppl 3:S67. 2755358
28. Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction 2006;21(2):352-7. [DOI: 10.1093/humrep/dei348]2755359
29. Lukaszuk K, Liss J, Kunicki M, Kuczynski W, Pastuszek E, Jakiel G, et al. Estradiol valerate pretreatment in short protocol GNRH-agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH-agonist cycles: a randomised controlled trial. BioMed Research International 2015;2015:1-6. 2755361
30. Broekmans JF, Verweij PJM, Eijkemans MJC, Mannaerts NMJL, Witjes H. Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Human Reproduction 2014;29(8):1688-97. 2755364
31. Nyboe Andersen A, Witjes H, Gordon K, Mannaerts B. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment. Human Reproduction 2011;26(12):3413-23. 2755365
32. Tavmergen E, von Mauw, Witjes H, Mannaerts B. Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun-1 Jul; Amsterdam, the Netherlands. 2009. 2755363
33. Obruca A, Fischl F, Huber J. Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Human Reproduction. 2002; Vol. 17 Abstract Book 1:89. 2755367
34. Porrati L, Vilela M, Viglierchio MI, Valcarcel A, Lombardi E, Marconi G. Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study. Human Reproduction 2010;25 Suppl 1(6):i102 Abstract no. O-259. 2755369
35. RaoofiZ, Aflatoonian A. Ovarian cysts formation during depot formulation of GnRH-a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles. Iranian Journal of Pharmaceutical Research 2008;7(2):109-13. 2755371
36. Rombauts L, Healy D, Norman RJ, Speirs A, Watkins B, Yovich J, et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Human Reproduction 2006;21(1):95-103. [DOI: 10.1093/humrep/dei302]2755373
37. Salat-Baroux J, Antoine JM, Alvarez S, Cornet D, Tibi C, Mandelbaum J, et al. Programmed ovulation induction and oocyte retrieval for in vitro fertilization. Journal of In Vitro Fertilization and Embryo Transfer 1988;5(3):153-7. 2755375
38. Shaker AG, Pittrof R, Zaidi J, Bekir J, Kyei-Mensah A, Tan SL. Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin-releasing hormone agonist in in vitro fertilization - a prospective randomized study. Fertility and Sterility 1995;64(4):791-5. 2755377
39. Tan SL, Biljan M. Fixed scheduling of long protocol of GNRH agonists - use of oral contraceptive (OC) or progestogen pre-treatment. Gynecological Endocrinology. 2001; Vol. 15 Suppl 2:31. 2755379
40. Vilela M, Marconi M, Zappacosta MP, Porrati L, Valcarcel A, Marconi G. Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study. Fertility and Sterility 2011; Vol. 96, issue 3 (supplement):S252, P-492. 2755381
41. Ye H, Huang G-N, Zeng P-H, Pei L. IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics 2009;26(2-3):105-11. 2755385
42. Aghahosseini M, Aleyassin A, Khodaverdi S, Esfahani F, Mohammadbeigi R, Movahedi S, et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics 2011;28:785-90. 2755389
43. al-Mizyen E, Sabatini L, Lower AM, Wilson CMY, al-Shawaf T, Grudzinskas JG. Does pretreatment with progestogen or oral contraceptive pills in low responders followed by the GnRHa flare protocol improve the outcome of IVF-ET?. Journal of Assisted Reproduction and Genetics 2000;17(3):140-6. 2755391
44. Anderson RE, Stein AL, Paulson RJ, Stanczyk FZ, Vijod AG, Lobo RA. Effects of norethindrone on gonadotropin and ovarian-steroid secretion when used for cycle programming during in vitro fertilization. Fertility and Sterility 1990;54(1):96-101. 2755393
45. Bakas P, Hassiakos D, Grigoriadis C, Vlahos NF, Liapis A, Creatsas G. Effect of a low dose combined oral contraceptive pill on the hormonal profile and cycle outcome following COS with a GnRH antagonist protocol in women over 35 years old. Gynecological Endocrinology 2014;30(11):825-9. 2755395
46. Bellver J, Albert C, Labarta E, Pellicer A. Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pill pretreatment. Fertility and Sterility 2007;87(5):1098-101. [DOI: 10.1016/j.fertnstert.2006.08.098]2755397
47. Benadiva CA, Ben-Rafael Z, Blasco L, Tureck R, Mastroianni LJ, Flickinger GL. Ovarian response to human menopausal gonadotropin following suppression with oral contraceptives. Fertility and Sterility 1988;50(3):516-8. 2755399
48. Bendikson K, Milki AA, Speck-Zulak A, Westphal LM. Comparison of GnRH antagonist cycles with and without oral contraceptive pretreatment in potential poor prognosis patients. Clinical and Experimental Obstetrics and Gynecology 2006;33(3):145-7. 2755401
49. Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues. Journal of Assisted Reproduction and Genetics 1998;15(10):599-604. 2755403
50. Branigan EF, Estes MA. Treatment of high responders with oral contraceptive pills (OC) before ovarian hyperstimulation for IVF. Fertility and Sterility 1998; Vol. 69, issue 3:599. 2755405
51. Brodt J, Taubert HD. Planned ovarian stimulation with preadministered contraceptives in an in-vitro fertilization program [Programmierte ovarielle stimulation mittels ovulationshemmer-vorbehandlung in einem in vitro fertilisations(IVF)-programm]. Archives of Gynecology and Obstetrics 1993;254(1-4):246-8. 2755407
52. Cédrin-Durnerin I, Hervé F, Huet-Pecqueux L, Kottler ML, Hugues JN. Progestogen pretreatment in the short-term protocol does not affect the prognostic value of the oestradiol flare-up in response to a GnRH agonist. Human Reproduction 1995;10(11):2904-8. 2755409
53. Cédrin-Durnerin I, Bulwa S, Hervé F, Martin-Pont B, Uzan M, Hugues JN. The hormonal flare-up following gonadotrophin-releasing hormone agonist administration is influenced by a progestogen pretreatment. Human Reproduction 1996;11(9):1859-63. 2755317
54. Cédrin-Durnerin I, Bulwa S, Hervé F, Pecqueux L, Uzan M, Hugues JN. Influence of norethisterone pretreatment on the initial flare-up induced by a gonadotrophin-releasing hormone agonist in a short protocol for IVF. Human Reproduction 1995;10 Abstract Book 2:116. 2755318
55. Chung MT, Tsai YC, Chen SH, Loo TC, Tang HH, Lin LY. Influence of pituitary suppression with triphasic or monophasic oral contraceptives on the outcome of in vitro fertilization and embryo transfer. Journal of Assisted Reproduction and Genetics 2006;23:343-6. [DOI: 10.1007/s10815-006-9056-y]2755411
56. Cohen J, Debache C, Solal P, Serkine AM, Achard B, Boujenah A, et al. Results of planned in-vitro fertilization programming through the pre-administration of the oestrogen-progesterone combined pill. Human Reproduction 1987;2(1):7-9. 2755413
57. Copperman AB, Mukherjee T, Sandler B, Grunfeld L, Bergh PA, Scott RT. Pre-treatment with oral contraceptive pill improves outcome in IVF cycles of poor-responders using the GnRH antagonist. Fertility and Sterility 2003; Vol. Suppl 3, 80:S108. 2755415
58. Couzinet B, Young J, Brailly S, Chanson P, Schaison G. Even after priming with ovarian steroids or pulsatile gonadotropin-releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhoea. Journal of Clinical Endocrinology and Metabolism 1995;80(7):2102-7. 2755417
59. Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Human Reproduction 1997;12(11):2359-65. 2755419
60. Davar R, Rahsepar M, Rahmani E. Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. Iranian Journal of Reproductive Medicine 2014;12 Suppl 1(6):71. 2755421
61. Davy C, Guibert J, Blanchet V, Nataf E, Olivennes F. The 'wash out' period do not create asynchrony of the follicle cohort when contraceptive pill is used to program GnRH antagonist IVF cycles. Human Reproduction. 2004; Vol. 19 Suppl 1:i5-6. 2755423
62. Olivennes F Sr, Davy C, Guibert J, Nataf E, Blanchet V. Asynchrony of the follicle cohort is not induced by the "wash out" period when contraceptive pill is used to program GnRH antagonist IVF cycles. Fertility and Sterility 2004; Vol. Suppl 2, 82:S234. 2755424
63. De Ziegler D, Brioschi PA, Benchaa C, Campana A, Ditesheim PJ, Fanchin R, et al. Programming ovulation in the menstrual cycle by a simple innovative approach: back to the future of assisted reproduction. Fertility and Sterility 1999;72(1):77-82. 2755426
64. Dickey RP, Sartor BM, Taylor SN, Lu PY, Rye PH, Pyrzak R. Oral contraceptives, not GnRH suppression, may be responsible for very low endogenous LH during IVF cycles. Fertility and Sterility 2001; Vol. Suppl 3, 76, issue 3:S237. 2755428
65. DitkoffEC, Prosser R, Zimmermann RC, Lindheim S, Sauer MV. The addition of norethindrone acetate to leuprolide acetate for ovarian suppression has no adverse effect on ovarian stimulation. Journal of Assisted Reproduction and Genetics 1997;14(2):92-6. 2755430
66. Doody KJ, Langley M, Marek D, Doody K. Oral contraceptive pre-treatment for IVF cycles employing recombinant FSH and a GnRH antagonist. Fertility and Sterility 2001; Vol. Suppl 1, 76, issue 3:S236. 2755432
67. Duvan CI, Berker B, Turhan NO, Satiroglu H. Oral contraceptive pretreatment does not improve outcome in microdose gonadotrophin-releasing hormone agonist protocol among poor responder intracytoplasmic sperm injection patients. Journal of Assisted Reproduction and Genetics 2008;25:89-93. [DOI: 10.1007/s10815-008-9203-8]2755434
68. Engels S, Blockeel C, Haentjens P, De Vos M, Camus M, Devroey P. How to avoid oocyte retrievals during weekend days using a GnRH antagonist protocol? A randomised controlled trial. Human Reproduction 2011;26 Suppl 1:i308 Abstract no: P-480. 2755436
69. Fanchin R, Schonauer L, Cunha Filho J, Kadoch I, Cohen Bacrie P, Frydman R. Luteal E2 administration reduces size and improves homogeneity of selectable follicles on cycle-day 3: bases for novel controlled ovarian hyperstimulation (COH) concepts. Fertility and Sterility 2001; Vol. Suppl 1, 76, issue 3:S90. 2755333
70. Fanchin R, Cunha Filho J, Schonauer L, Kadoch I, Cohen Bacri P, Frydman R. Co-ordination of early antral follicles by luteal estradiol administration: basis for novel controlled ovarian hyperstimulation. Human Reproduction. 2002; Vol. 17 Abstract Book 1:88-9. 2755438
71. Fanchin R, Cunha-Filho JS, Schonauer LM, Kadoch IJ, Cohen-Bacri P, Frydman R. Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens. Fertility and Sterility 2003;79(2):316-21. 2755439
72. Feichtinger W, Babor P, Herczeg KM, Heyda M, Hoffmann R, Plockinger B, et al. Side effects of oral contraceptives in the first treatment cycle. Weiner Medizinische Wochenschrift 1991;141(18-19):412-5. 2755441
73. Fisch B, Royburt M, Pinkas H, Avrech OM, Goldman GA, Bar J, et al. Augmentation of low ovarian response to superovulation before in vitro fertilization following priming with contraceptive pills. Israel Journal of Medical Sciences 1996;32(12):1172-6. 2755443
74. Forman RG, Demouzon J, Feinstein MC, Testart J, Frydman R. Studies on the influence of gonadotrophin-levels in the early follicular phase on the ovarian response to stimulation. Human Reproduction 1991;6(1):113-7. 2755445
75. Frederick J, DaCosta V, Wynter S, Reid M, Frederick C, McKenzie C. Effect of the oral contraceptive pill on patients undergoing controlled ovarian hyperstimulation. West Indian Medical Journal 2004;53(1):39-43. 2755447
76. Frydman R, Forman R, Rainhorn JD, Belaisch-Allart J, Hazout A, Testart J. A new approach to follicular stimulation for in vitro fertilization: programmed oocyte retrieval. Fertility and Sterility 1986;46(4):657-62. 2755449
77. Galera F, Verdu V, Villafañex V, Garijo E, Rayward J, Bajo JM. Comparison of plasmatic steroid levels with and without previous oral contraceptive administration in GnRH antagonist IVF cycles. Fertility and Sterility 2004; Vol. Suppl 2, 82:S32. 2755451
78. Gerli S, Remohi J, Partrizio P, Borrero C, Balmaceda JP, Silber SJ, et al. Programming of ovarian stimulation with norethindrone acetate in IVF/GIFT cycles. Human Reproduction 1989;4(7):746-8. 2755453
79. Ghanem M, Bediary MH, Helal AS, et al. Is adding estradiole (E2) to progesterone (P) luteal support in high responder long GnRH agonist ICSI cycles detrimental to outcome? Randomised controlled trial (RCT). Fertility & Sterility 2015;104 Suppl(3):e224. 2755455
80. Godin PA, Gaspard O, Jouan C, Thonon F, Hincourt N, Ravet S, et al. Importance of estradiol priming in in-vitro maturation cycles. Human Reproduction 2003;18 Suppl 1:153. 2755457
81. Gomez E, Ballesteros A, Landeras J, Munoz M, Martinez MC. Preparation of endometrium with oral oestradiol valerate versus transdermal oestradiol for cryopreserved embryo transfer: a prospective randomized study. Human Reproduction 2000;15:175-6. 2755459
82. Gonen Y, Jacobson W, Casper RF. Gonadotropin suppression with oral contraceptives before in vitro fertilization. Fertility and Sterility 1990;53(2):282-7. 2755461
83. Gonzalez P, Maloul S, Ciuffardi I, Frederick JL, Balmaceda JP, Asch RH. The use of progestins for programming assisted reproductive cycles and gonadotropin-releasing hormone agonist flare-up protocols in older patients. Fertility and Sterility 1995;63(2):249-51. 2755463
84. Greco E, Litwicka K, Arrivi C, Varricchio MT, Caragia A, Greco A, et al. The endometrial preparation for frozen-thawed euploidblastocyst transfer: a prospective randomized trial comparing clinical results from natural modified cycle and exogenous hormone stimulation with GnRH agonist. Journal of Assisted Reproduction and Genetics 2016;33:873-84. [DOI: 10.1007/s10815-016-0736-y]5670895
85. Haydardedeoglu B, Kilicdag EB, Parlakgummus AH, Zeyneloglu HB. IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist protocol in women with PCOS: a randomised trial. Archives of Gynecology and Obstetrics 2012;286:763-9. 2755465
86. Hugues JN, Attalah M, Hervé F, Martin-Pont B, Kottler ML, Santarelli J. Effects of short-term GnRH agonist - human menopausal gonadotropin stimulation in patients pre-treated with progestogen. Human Reproduction 1992;7(8):1079-84. 2755467
87. Jung H, Roh HK. The effects of E2 supplementation from the early proliferative phase to the late secretory phase of the endometrium in hMG-stimulated IVF-ET. Journal of Assisted Reproduction and Genetics 2000;17(1):28-33. 2755469
88. Karande VC, Latash WDZ, Birkenkamp T, Cavanaugh J, Melone K, Hazlett D. Preliminary report of a prospective randomized controlled trial comparing the use of NuvaRing® to Desogen® in in vitro fertilization cycles with ganirelix acetate. Fertility and Sterility 2004; Vol. Suppl 2, 82:S31-2. 2755471
89. Keltz MD, Gera PS, Skorupski J, Stein DE. Comparison of FSH flare with and without pretreatment with oral contraceptive pills in poor responders undergoing in vitro fertilization. Fertility and Sterility 2007;88(2):350-3. [DOI: 10.1016/j.fertnstert.2006.11.123]2755473
90. Keltz MD, Sharma P, Stein DE. Comparison of FSH flare in poor responders undergoing in vitro fertilization (IVF) with and without prior oral contraceptive suppression. Fertility and Sterility 2003; Vol. 80:S107. 2755474
91. Kovacs P, Barg PE, Witt BR. Hypothalamic-pituitary suppression with oral contraceptive pills does not improve outcome in poor responder patients undergoing in vitro fertilization-embryo transfer cycles. Journal of Assisted Reproduction and Genetics 2001;18(7):391-4. 2755476
92. Kreiner D, diLandro R, Moschella J. Study of IVF success with pituitary suppression prior to follistim/HMG stimulation in ganirelix cycles using oral contraceptives and estrace. Fertility & Sterility 2007;Vol 88 Suppl 1:284, abstract no. 534. 2755478
93. Leondires MP, Escalpes M, Segars JH, Scott RT, Miller BT. Microdose follicular phase gonadotropin-releasing hormone agonist (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization. Fertility and Sterility 1999;72(6):1018-23. 2755480
94. Letterie GS. Inhibition of gonadotropin surge by a brief mid-cycle regimen of ethinyl estradiol and norethindrone: possible role in in vitro fertilization. Gynecological Endocrinology 2000;14(1):1-4. 2755482
95. Lewin A, Fatum M, Shufaro Y, Simon A, ReubinoffB, Laufer N, et al. Artificial endometrial preparation for frozen-thawed embryo transfer using oral oestradiol and a new low-dose vaginal progesterone preparation: Endometrin tablets. Human Reproduction 2001; Vol. Suppl 1, 16:152. 2755484
96. Lewin A, Pisov G, Turgeman R, Fatum M, Shufaro Y, Simon A, et al. Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study. Gynecological Endocrinology 2002;16(2):131-6. 2755485
97. Lindheim SR, Barad DH, Witt B, DitkoffE, Sauer MV. Short-term gonadotropin suppression with oral contraceptives benefits poor responders prior to controlled ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics 1996;13(9):745-7. 2755487
98. Liu KE, Alhajri M, Greenblatt E. A randomized controlled trial of NuvaRing versus combined oral contraceptive pills for pretreatment in in vitro fertilization cycles. Fertility and Sterility 2011;96(3):605-8. 2755489
99. Loutradis D, Stefanidis K, Drakakis P, Kallianidis K, El Sheikh A, Milingos S, et al. Does pre-treatment with micronized progesterone affect the ovarian response to a gonadotropin releasing hormone agonist flare-up protocol?. Gynecological Endocrinology 2003;17(2):101-6. 2755491
100. Martínez F, Boada M, Coroleu B, Clua E, Parera N, Rodríguez I, et al. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH. Human Reproduction 2006;21(8):2121-5. 2755493
101. Mashiach S, Dor J, Goldenberg M, Shalev J, Blankstein J, Rudake E, et al. Protocols for induction of ovulation - the concept of programmed cycles. Annals of the New York Academy of Sciences 1988;541:37-45. 2755495
102. Mashiach S, Dor J, Goldenberg M, Shalev J, Levran D, Rudak E, et al. Programmed oocyte retrieval: clinical and biological effects of oral contraceptives administered before in vitro fertilization. Gynecological Endocrinology 1989;3(2):107-15. 2755496
103. Meldrum D, Scott R, Levy MJ, Alper M, Noyes N. A pilot study to assess oral contraceptive (OC) pretreatment in women undergoing controlled ovarian hyperstimulation (COH) in ganirelix acetate cycles. Fertility and Sterility 2002; Vol. Suppl 1, 78, issue 3:S176. 2755498
104. Meldrum DR, Cassidenti DL, Rosen GF, Yee B, Wisot AL. Oral contraceptive pretreatment and half dose of ganirelix does not excessively suppress LH and may be an excellent choice for scheduling IUI cycles. Journal of Assisted Reproduction and Genetics 2008;25:417-20. [DOI: 10.1007/s10815-008-9244-z]2755500
105. Merviel P, Cabry-Goubet R, Lourdel E, Devaux A, Belhadri-Mansouri N, Copin H, et al. Comparative prospective study of 2 ovarian stimulation protocols in poor responders: effect on implantation rate and ongoing pregnancy. Reproductive Health 2015;12:52. 2755502
106. Scheffler F, Merviel P, Lourdel E, et al. Contraceptive pill and gonadotropin-releasing hormone (GnRH) flare-up agonist versus GnRH antagonist protocol in poor responders: lessons to a prospective study. Human Reproduction 2015;30 Suppl:i295 Abstract no: p-410. 2755503
107. Min JK, Claman P. Oral contraceptive (OC) pre-treatment does not influence oocyte yield in poor responders undergoing gonadotropin releasing hormone (GnRH) antagonist cycles for in vitro fertilization (IVF). Fertility and Sterility 2005; Vol. Suppl 1, 84:S45-6. 2755505
108. Mirkin S, Stadtmauer LA, Gibbons WE, Oehninger S. Clinical and endocrine impact of pretreatment with oral contraceptive pills in poor responders undergoing IVF with a combination of microdose flare leuprolide acetate and high dose gonadotropins. Fertility and Sterility 2003; Vol. Suppl 3, 80:S190-1. 2755507
109. Mulangi AS, Nelson-White TM, Racowsky C, Gelety TJ. Follicular phase endocrine response to oral contraceptives (OCs) followed by gonadotropin releasing hormone agonist (GnRHa) for down-regulation prior to controlled ovarian hyperstimulation (COH) for the purpose of IVF. Fertility and Sterility 1997; Vol. Suppl 1, 68:S6. 2755509
110. Neal GS, Sultan KM, Liu HC, Davis OK, Rosenwaks Z. A dual approach to ovarian suppression using oral contraceptive pills and leuprolide acetate in high responder patients undergoing IVF. Fertility and Sterility 1993;60(5):S111. 2755511
111. Pados G, Tarlatzis BC, Bontis J, Lagos S, Papadimas J, Spanos E, et al. Evaluation of different ovarian stimulation protocols for in vitro fertilization. Gynecological Endocrinology 1995;9:103-12. [DOI: 10.3109/09513599509160198]2755513
112. Palomba S, Falbo A, Orio F, Russo T, Tolino A, Zullo F. Pretreatment with oral contraceptives in infertile anovulatory patients with polycystic ovary syndrome who receive gonadotropins for controlled ovarian stimulation. Fertility and Sterility 2008;89(6):1838-42. [DOI: 10.1016/j.fertnstert.2007.05.035]2755515
113. Pinkas H, Sapir O, Avrech OM, Ben-Haroush A, Ashkenzi J, Fisch B, et al. The effect of oral contraceptive pill for cycle scheduling prior to GnRH-antagonist protocol on IVF cycle parameters and pregnancy outcome. Journal of Assisted Reproduction and Genetics 2008;25:29-33. [DOI: 10.1007/s10815-007-9189-7]2755517
114. Ramsewak SS, Duffy S, Taylor J, Woodward B. The oral contraceptive pill effectively permits cycle batching for an intermittent in vitro fertilization programme in Trinidad and Tobago. West Indian Medical Journal 2005;54(2):127-9. 2755519
115. Rashidi B, Nasiri R, Rahmanpour H, Shahrokh Tehraninejad E, Deldar M. Luteal phase estradiol versus luteal phase GnRH antagonist administration: their effects on antral follicular size coordination and basal hormonal levels. Iranian Journal of Reproductive Medicine 2011;9(4):315-8. 2755521
116. Russell JB, Knezevich KM, Fabian KF, Dickson JA. Unstimulated immature oocyte retrieval: early versus mid follicular endometrial priming. Fertility and Sterility 1997;67(4):616-20. 2755523
117. Sanghvi A, Noyes N, Krey LC. An oral contraceptive (OCP) microdose flare leuprolide acetate (LA) stimulation protocol is useful for poor prognosis patients undergoing in vitro fertilization (IVF). Fertility and Sterility 2002; Vol. Suppl 1, 78:S149. 2755525
118. Schoolcraft W, Schlenker T, Gee M, Stevens J, Wagley L. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertility and Sterility 1997;67(1):93-7. 2755527
119. Steinkampf MP, Hammond KR, Blackwell RE. Effect of estrogen/progestin administration on the ovarian response to gonadotropins: a randomized, prospective study. Fertility and Sterility 1991;55(3):642-3. 2755529
120. Surrey ES, Cedars MI. The effect of gonadotropin suppression on the induction of ovulation in premature ovarian failure patients. Fertility and Sterility 1989;52(1):36-41. 2755531
121. Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertility and Sterility 1998; Vol. 69, issue 3:419-24. 2755533
122. Talebian S, Krey LC, Noyes N. Use of oral contraceptives with GnRH antagonists and recombinant gonadotropins in IVF cycles have no deleterious effect on pregnancy outcome. Fertility and Sterility 2004; Vol. Suppl 2, 82:S234. 2755535
123. Talebian S, Krey LC, Reh A, Granguly N, Liu M, Noyes N. Oral contraceptive (OC) pre-treatment in GnRH antagonist (ANT) cycles is a reasonable option to control the timing of IVF cycles. Fertility and Sterility 2007; Vol. Suppl 1, 88:S291. 2755537
124. Tarlatzis BC, Pazaitou K, Bili H, Bontis J, Papadimas J, Lagos S, et al. Growth hormone, oestradiol, progesterone and testosterone concentrations in follicular fluid after ovarian stimulation with various regimes for assisted reproduction. Human Reproduction 1993;8(10):1612-6. 2755539
125. Tartagni M, Cicinelli E, De Pergola G, De Salvia MA, Lavopa C, Loverro G. Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial. Fertility and Sterility 2007;87(4):858-61. [DOI: 10.1016/j.fertnstert.2006.08.086]2755541
126. Tehraninejad ES, Nasiri R, Rashidi B, Haghollahi F, Ataie M. Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Archives of Gynecology & Obstetrics 2010;282(3):319-25. 2755543
127. Wang B, Sun HX, Hu YL, Chen H, Zhang NY. Application of GnRH-antagonist to IVF-ET for patients with poor ovarian response. National Journal of Andrology [Zhonghua Nan Ke Xue] 2008;14(5):423-6. 2755383
128. Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y. Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF a double-blind randomized crossover clinical trial. Medicine 2016;95(9):1-8. 5670897
129. Wei D, Shi Y, Li J, Wang Z, Zhang L, Sun Y, et al. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome. Human Reproduction 2016;32(2):1-8. [DOI: 10.1093/humrep/dew325]5670899
130. Weisman Z, Dirnfeld M, Lissak A, Sorokin Y, Abramovici H. Oral contraceptive pills and follicular fluid hormones in an in vitro fertilization program. Fertility and Sterility 1989;52(3):451-3. 2755545
131. Yokota Y, Yokota M, Yokota H, Makita M, Sato S, Araki Y. A novel procedure for improving pregnancy rates in frequent repeated IVF failure: estrogen rebound combined with GnRH agonist flare. Human Reproduction 2006;21 Suppl 1:i130-1. 2755547
132. Yoshida A, Kakinuma M, Matsuba T, Seida K, Suzuki H, Tanaka M. Effectiveness of using estradiol-GnRH antagonist protocol with unsuccessful oral contraceptive pill-GnRH antagonist protocol cases (full term pregnancies had not resulted) in in-vitro fertilization (IVF) cycles. Fertility and Sterility 2005; Vol. Suppl 1, 84:S45. 2755549
133. Youssef M, van Wely M, Al-Inany H, Madani T, Jahangiri N, Khodabakhshi S, et al. A mild ovarian stimulation in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial. Human Reproduction 2017;32(1):112-8. 5670900
134. Youssef M, van Wely M, Al-Inany H, Madani T, Jahangiri N, Khodabakhshi S, et al. Mild versus standard ovarian stimulation in poor responder women undergoing IVF and ICSI (prima) - multicenter randomised controlled study. Human Reproduction 2014;29:i50-1. 2755387
135. Zhao JZ, Lin XH, Huang XF, Lin JJ, Lin WQ, Ye BL. Effect of desogestrel and ethinyl estradiol pretreatment in superovulation cycles with short protocol. Chinese Journal of Obstetrics and Gynecology [Zhonghua Fu Chan Ke Za Zhi] 2008;43(2):102-5. 2755551
136. Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews 2016, Issue 4. [DOI: 10.1002/14651858.CD001750.pub4]
137. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD004425.pub3]
138. Awadalla SG, Friedman CI, Chin NW, Dodds W, Park JM, Kim MH. Follicular stimulation for in vitro fertilization using pituitary suppression and human menopausal gonadotropins. Fertility and Sterility 1987;48(5):811-5.
139. Barmat LI, Chantilis SJ, Hurst BS, Dickey RP. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility 2005;83(2):321-30. [DOI: 10.1016/j.fertnstert.2004.06.076]
140. Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility 1998;70(6):1063-9.
141. Cohen BL, Katz M. Pituitary and ovarian function in women receiving hormonal contraception. Contraception 1979;20(5):475-87.
142. De Ziegler D, Jaaskelainen AS, Brioschi PA, Fanchin R, Bulletti C. Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH). Human Reproduction 1998;13(3):561-4.
143. Dodson WC. Role of gonadotropin releasing hormone agonists in ovulation induction. Journal of Reproductive Medicine 1989;34(1):76-9.
144. Thomson Reuters. EndNote. Version X1. New York: Thomson Reuters, 2008.
145. Erkkola R. Recent advances in hormonal contraception. Obstetrics and Gynecology 2007;19:547-53.
146. European Society of Human Reproduction and Embryology. 32nd annual meeting of the European Society of Human Reproduction and Embryology. Helsinki, Finland 2016. Human Reproduction 2016;31 Suppl 1:Abstract book.
147. Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier J. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Contraception 1984;29(4):305-18.
148. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed prior to 28 October 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
149. Griesinger G, Venetis CA, Marx T, Diedrich K, Tarlatzis BC, Kolibianakis EM. Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertility and Sterility 2008;90(4):1055-63. [DOI: 10.1016/j.fertnstert.2007.07.1354]
150. Griffin PD, Rowe PJ, Vayena E, editor(s). Medical, ethical and social aspects of assisted reproduction. Current practices and controversies in assisted reproduction: report of a WHO meeting. Geneva, Switzerland: World Health Organization 2002. [ISBN 92 4 159030 0]
151. Harwood K, Vuguin P, DiMartino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Hormone Research 2007;68(5):209-17. [DOI: 10.1159/000101538]
152. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
153. Huirne JA, Hugues JN, Pirard C, Fischl F, Sage JC, Pouly JL, et al. Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction 2006;21(6):1408-15. [10.1093/humrep/del030]
154. Irvine GA, Cameron IT. Medical management of dysfunctional uterine bleeding. Best Practice and Research in Clinical Obstetrics and Gynaecology 1999;13(2):189-202.
155. Le Nestour E, Marraoui J, Lahlou N, Roger M, De Ziegler D, Bouchard P. Role of estradiol in the rise in follicle-stimulating hormone levels during the luteal-follicular transition. Journal of Clinical Endocrinology and Metabolism 1993;77(2):439-42.
156. Farquhar C, Clarke J, Lethaby A, Thomas J, Proctor M, Barlow D, et al. Cochrane Menstrual Disorders and Subfertility Group, About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). Available at www.thecochranelibrary.com 2008.
157. Moher D, Liberati A, TetzlaffJ, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. BMJ 2009;339:2535.
158. Moudgal RN, Jagannadha Rao A, Murthy GSRC, Neelakanta R, Banavar SR, Kotagi SG, et al. Effect of intranasal administration of norethisterone and progesterone on pituitary and gonadal function in adult male and female bonnet monkeys (Macaca radiata). Fertility and Sterility 1985;44(1):120-4.
159. Pandian Z, Bhattacharya S, Vale L, Templeton A. In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD003357.pub2]
160. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
161. Scottish Intercollegiate Guidelines Network. Search filters. www.sign.ac.uk/methodology/filters.html#random (accessed 18 November 2008).
162. Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Human Reproduction Update 2006;12(4):333-40. [DOI: 10.1093/humupd/dml001]
163. Van Wely M, Westergaard LG, Bossuyt PM, Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD003973]
164. Smulders B, van Oirschot SM, Farquhar C, Rombauts L, Kremer JAM. Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews 2006, Issue 7. [DOI: 10.1002/14651858.CD006109]
165. Smulders B, van Oirschot SM, Farquhar C, Rombauts L, Kremer JAM. Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD006109.pub2]